Continuous processing, already conventional in many manufacturing fields, has been establishing itself in biopharma, which is starting to realize continuous processing’s compelling advantages: ...
Only a handful of biopharmaceutical companies have heard of a small microbioreactor developer that calls itself Erbi Biosystems. It hasn’t been in stealth mode. Its engineer-founders just weren’t ...
Ustekinumab is a human monoclonal antibody (mAb) that selectively targets the p40 protein, a component common to both interleukin (IL)-12 and IL-23 cytokines, which play crucial roles in treating ...
The demand for producing therapeutic recombinant proteins is generating a renewed interest in perfusion cell culture technologies, leading to the development of cell culture media that can support ...
Erbi's differentiated 2 ml micro-bioreactor platform technology, Breez ™, enables rapid lab testing for bioprocessing scale up Allows MilliporeSigma to offer full range of bioreactors, from 2ml to ...
The biopharmaceutical industry is expanding rapidly, driven by an increasing demand for complex biomedicines. Today, manufacturing biomolecules presents unique challenges, like cost pressure and ...
Achieving high cell densities in long-term cultures is often a challenge facing bioprocessing manufacturers, and one that requires the support of optimal media. FUJIFILM Irvine Scientific recently sat ...
Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors. Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and carboplatin (TIC) in ...
Recent advances in cell culture technology have transformed the landscape of viral vaccine production, offering enhanced scalability, efficiency and adaptability compared to traditional egg‐based or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback